Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • toripalimab

    - PMLiVE

    LEO Pharma receives NICE approval for chronic hand eczema cream

    The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable

    - PMLiVE

    LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema

    The cream is now the first treatment approved by the regulator specifically for this patient population

    - PMLiVE

    LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

    Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

    EU flag

    EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

    The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

    - PMLiVE

    LEO Pharma and the Parker Institute join forces to advance dermatology research

    The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research

    - PMLiVE

    LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

    Approximately 125 million people worldwide are affected by some form of the inflammatory condition

    - PMLiVE

    BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

    Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

    - PMLiVE

    LEO and DEBRA Research partner to advance epidermolysis bullosa treatments

    There is currently no cure for the group of rare inherited skin disorders

    - PMLiVE

    LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab

    The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    LEO Pharma’s Anzupgo cream granted MHRA approval to treat chronic hand eczema

    Anzupgo is the first topical pan-JAK inhibitor approved specifically for adults with moderate-to-severe cases

    - PMLiVE

    BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

    Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links